

Použité zkratky:

KV = kardiovaskulární; **DM** = diabetes mellitus; **GLP-1** = glukagonu podobný peptid 1; **TK** = krevní tlak

Reference:

1. Aktuální SPC přípravku Saxenda®
2. Pi-Sunyer X, Astrup A, Fujioka K, et al; for the SCALE Obesity and Prediabetes NN8022-1839 Study Group. A randomized, controlled trial of 3.0 mg of liraglutide in weight management. *N Engl J Med*. 2015;373(1):11-22.
3. le Roux CW, Astrup A, Fujioka K, et al; for the SCALE Obesity and Prediabetes NN8022-1839 Study Group. 3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: a randomised, double-blind trial. *Lancet*. 2017;389(10077):1399-1409.
4. Wadden TA, Hollander P, Klein S, et al; on behalf of NN8022-1923 Investigators. Weight maintenance and additional weight loss with liraglutide after low-calorie-diet-induced weight loss: the SCALE Maintenance randomized study. *Int J Obes (Lond)*. 2013;37(11):1443-1451. [Erratum: *Int J Obes (Lond)*. 2013;37:1514. doi:10.1038/ijo.2013.148.]
5. Bray GA, Kim KK, Wilding JPH; on behalf of the World Obesity Federation. Obesity: a chronic relapsing progressive disease process. A position statement of the World Obesity Federation. *Obes Rev*. 2017;18(7):715-723.
6. Pi-Sunyer X, Astrup A, Fujioka K, et al; for the SCALE Obesity and Prediabetes NN8022-1839 Study Group. A randomized, controlled trial of 3.0 mg of liraglutide in weight management. *N Engl J Med*. 2015;373(1):11-22 and supplementary appendix. doi:10.1056/NEJMoa1411892.
7. Marso SP, Daniels GH, Brown-Frandsen K, et al; the LEADER Steering Committee on behalf of the LEADER Trial Investigators. Liraglutide and cardiovascular outcomes in type 2 diabetes. *N Engl J Med*. 2016;375(4):311-322.
8. Marso SP, Poulter NR, Nissen SE, et al. Design of the liraglutide effect and action in diabetes: evaluation of cardiovascular outcome results (LEADER) trial. *Am Heart J*. 2013;166(5):823-830.
9. Marso SP, Daniels GH, Brown-Frandsen K, et al; the LEADER Steering Committee on behalf of the LEADER Trial Investigators. Liraglutide and cardiovascular outcomes in type 2 diabetes. *N Engl J Med*. 2016;375(4):311-322 and supplementary appendix.
http://www.nejm.org/doi/suppl/10.1056/NEJMoa1603827/suppl_file/nejmoa1603827_appendix.pdf.
10. GBD 2015 Obesity Collaborators. Health effects of overweight and obesity in 195 countries over 25 years. *N Engl J Med*. 2017;377(1):13-27.
11. American Diabetes Association. Diagnosis and classification of diabetes mellitus. *Diabetes Care*. 2010;33(suppl1):S62-S69.
12. Response to request for supplementary information from PRAC (dated 24 January 2017) and CHMP (dated 23 February 2017) EMEA/H/C/003780/II/0011. Bagsværd, Denmark: Novo Nordisk A/S; 23 February 2017.
13. Internal calculations by Novo Nordisk based on IQVIA™ database: based on Novo Nordisk ex-factory volume sales by month. Each patient assumed to be on 3 mg liraglutide per day.
14. Caterson ID, Alfadda AA, Auerbach P, et al. Gaps to bridge: misalignment between perception, reality and actions in obesity *Diabetes Obes Metab*. 2019;21(8):1914-1924.